Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00483132

Enrollment

232

Registered

2007-06-06

Start date

1994-09-30

Completion date

2002-04-30

Last updated

2007-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia, Lymphocytic, Acute

Brief summary

Improved outcome of high risk lymphoblastic leukemia (ALL) with laite high dose therapy. High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma (LBL).

Detailed description

Comparison between two autograf therapeutic strategies in high risk patients Ramdomised comparison between maintenance treatment with or not interferon alpha 2 a

Interventions

DRUGinterferon alpha 2a

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

15 Years to 65 Years

Healthy volunteers

Inclusion criteria

* ALL high risk or low risk or lymphoblastic lymphoma * age 15-55 years old * informed consent signed

Exclusion criteria

* patients previously treated with a chemotherapy or alpha-interferon * ALL 3 (burkitt like)

Design outcomes

Primary

Measure	Time frame
overall survival	time to death

Secondary

Measure	Time frame
Efficacy of study treatments	time to end of treatment

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026